healthneutral
Mixed Migraine Relief: A Real-World Study
Friday, February 21, 2025
One thing to consider is that the study was retrospective. This means it looked back at data that was already collected. It wasn't a controlled experiment where patients were randomly assigned to different treatments. This can make it harder to draw firm conclusions.
Another point is that migraines are complex. They can be caused by many different things, and what works for one person might not work for another. This study doesn't tell us why the combination didn't work better. It just shows that it didn't, in this particular group of patients.
The study also didn't look at long-term effects. It's possible that the combination could be more effective over a longer period. But we don't know that from this study.
It's also important to note that migraine treatments can be expensive. Adding a second drug to the mix could increase costs. This is something to consider, especially if the combination isn't clearly more effective.
In the end, this study adds to our understanding of migraine treatments. It shows that combining atogepant and onabotulinumtoxinA is generally safe. But it doesn't show that it's clearly more effective than using onabotulinumtoxinA alone. More research is needed to figure out the best ways to treat chronic migraines.
Actions
flag content